Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Bioavailability Enhancement: Drug Permeability Enhancement

Bioavailability Enhancement: Drug Permeability Enhancement

After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt secretion,...

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Cisplatin: process and future.

Journal of B.U.ON. : official journal of the Balkan Union of Oncology·2013

Same author

High-dose tamoxifen in breast cancer bone metastasis.

Journal of B.U.ON. : official journal of the Balkan Union of Oncology·2013

Same author

Maintenance chemotherapy or not in ovarian cancer stages IIIA, B, C, and IV after disease recurrence.

Journal of B.U.ON. : official journal of the Balkan Union of Oncology·2013

Same author

Combination of three cytotoxic agents in small-cell lung cancer.

Cancer chemotherapy and pharmacology·2012

Same author

Two consecutive days of treatment with liposomal cisplatin in non-small cell lung cancer.

Oncology letters·2012

Same author

Erlotinib treatment in pretreated patients with non-small cell lung cancer: A Phase II study.

Oncology letters·2012

Same journal

Corrigendum to "Alkyl Length Effects on the DNA Transport Properties of Cu (II) and Zn(II) Metallovesicles: An <i>In Vitro</i> and <i>In Vivo</i> Study".

Journal of drug delivery·2020

Same journal

Dry Powder and Budesonide Inhalation Suspension Deposition Rates in Asthmatic Airway-Obstruction Regions.

Journal of drug delivery·2019

Same journal

Advanced Lipid Technologies® (ALT®): A Proven Formulation Platform to Enhance the Bioavailability of Lipophilic Compounds.

Journal of drug delivery·2019

Same journal

Rate of Drug Coating Dissolution Determines In-Tissue Drug Retention and Durability of Biological Efficacy.

Journal of drug delivery·2019

Same journal

Alkyl Length Effects on the DNA Transport Properties of Cu (II) and Zn(II) Metallovesicles: An <i>In Vitro</i> and <i>In Vivo</i> Study.

Journal of drug delivery·2018

Same journal

Potential of Cocoa Pod Husk Pectin-Based Modified Release Capsules as a Carrier for Chronodelivery of Hydrocortisone in Sprague-Dawley Rats.

Journal of drug delivery·2018

See all related articles

Search research articles

Related Experiment Video

Updated: May 29, 2026

Testing the In Vitro and In Vivo Efficiency of mRNA-Lipid Nanoparticles Formulated by Microfluidic Mixing

Testing the In Vitro and In Vivo Efficiency of mRNA-Lipid Nanoparticles Formulated by Microfluidic Mixing

Published on: January 20, 2023

Lipoplatin formulation review article.

G P Stathopoulos¹, T Boulikas

¹First Oncology Clinic, Errikos Dunant Hospital, Athens, Greece.

Journal of Drug Delivery

|September 10, 2011

Summary

This summary is machine-generated.

Lipoplatin, a novel liposomal encapsulation of cisplatin, demonstrates superior efficacy and reduced side effects compared to traditional cisplatin in non-squamous non-small-cell lung cancer clinical trials.

More Related Videos

Formulating and Characterizing Lipid Nanoparticles for Gene Delivery using a Microfluidic Mixing Platform

Formulating and Characterizing Lipid Nanoparticles for Gene Delivery using a Microfluidic Mixing Platform

Published on: February 25, 2021

Solid Lipid Nanoparticles (SLNs) for Intracellular Targeting Applications

Solid Lipid Nanoparticles (SLNs) for Intracellular Targeting Applications

Published on: November 17, 2015

Related Experiment Videos

Last Updated: May 29, 2026

Testing the In Vitro and In Vivo Efficiency of mRNA-Lipid Nanoparticles Formulated by Microfluidic Mixing

Testing the In Vitro and In Vivo Efficiency of mRNA-Lipid Nanoparticles Formulated by Microfluidic Mixing

Published on: January 20, 2023

Formulating and Characterizing Lipid Nanoparticles for Gene Delivery using a Microfluidic Mixing Platform

Formulating and Characterizing Lipid Nanoparticles for Gene Delivery using a Microfluidic Mixing Platform

Published on: February 25, 2021

Solid Lipid Nanoparticles (SLNs) for Intracellular Targeting Applications

Solid Lipid Nanoparticles (SLNs) for Intracellular Targeting Applications

Published on: November 17, 2015

Area of Science:

Oncology
Nanotechnology
Pharmaceutical Sciences

Background:

Cisplatin is a cornerstone chemotherapy agent, but its efficacy is limited by significant toxicity.
Liposomal encapsulation offers a strategy to improve drug delivery and reduce side effects.
Lipoplatin utilizes patented technology for targeted delivery of cisplatin via nanoparticles.

Purpose of the Study:

To review the molecular mechanisms, preclinical, and clinical data of Lipoplatin.
To evaluate Lipoplatin's efficacy and safety profile in various cancer types.
To assess Lipoplatin's potential to replace or enhance cisplatin therapy.

Main Methods:

Review of published preclinical and clinical trial data.
Analysis of molecular mechanisms of liposomal cisplatin.
Examination of data from three randomized Phase II and III clinical trials.

Main Results:

Lipoplatin has been successfully administered in multiple clinical trials.
Clinical data primarily focuses on non-small-cell lung cancer, with additional data in pancreatic, breast, and head and neck cancers.
A Phase III study showed Lipoplatin's superiority over cisplatin in non-squamous non-small-cell lung cancer, with simultaneous reduction in side effects.

Conclusions:

Lipoplatin represents a significant advancement in platinum-based chemotherapy.
Lipoplatin demonstrates improved efficacy and a better safety profile than cisplatin.
Lipoplatin is expected to expand therapeutic applications and potentially replace cisplatin.